https://vitalspanwire.com/news/fda-approves-pritelivir-refractory-herpes-immunocompromised-adultsVitalspan Wireen2026-10-10T21:01:46.924ZFDA approves pritelivir for refractory herpes lesions in immunocompromised adultshttps://vitalspanwire.com/news/urolithin-a-trial-vascular-endpoint-brain-responseVitalspan Wireen2026-10-10T16:02:22.056ZUrolithin A trial finds no significant vascular benefit on primary endpointhttps://vitalspanwire.com/news/nopark-nicotinamide-riboside-parkinsons-clinical-outcomesVitalspan Wireen2026-10-10T11:01:31.048ZNicotinamide riboside fails to improve Parkinson outcomes in NOPARK trialhttps://vitalspanwire.com/news/survaxm-survive-glioblastoma-overall-survival-endpointVitalspan Wireen2026-10-09T21:01:38.042ZSurVaxM misses overall survival endpoint in glioblastoma trialhttps://vitalspanwire.com/news/fda-atezolizumab-adjuvant-stage-iii-dmmr-colon-cancerVitalspan Wireen2026-10-09T16:01:45.576ZFDA approves atezolizumab after surgery for stage III dMMR colon cancerhttps://vitalspanwire.com/news/dog-aging-body-size-epigenetic-aging-transposable-elementsVitalspan Wireen2026-10-09T11:01:44.564ZDog-aging study links larger body size to faster epigenetic aging